Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_1
1
17%
Ph phase_4
4
67%
Ph phase_3
1
17%

Phase Distribution

1

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
4(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(2)
Terminated(3)
Other(1)

Detailed Status

Completed2
Terminated2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 31 (16.7%)
Phase 44 (66.7%)

Trials by Status

completed233%
terminated233%
unknown117%
withdrawn117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_4

A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers

NCT01327937
withdrawnphase_4

A Post-Marketing Clinical Study of Apligraf for Venous Leg Ulcers

NCT00648674
terminatedphase_4

A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa

NCT01619670
unknownphase_4

A Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®

NCT02011724
completedphase_1

A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids

NCT00587587
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01327937Phase 4

A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers

Completed
NCT00648674Phase 4

A Post-Marketing Clinical Study of Apligraf for Venous Leg Ulcers

Withdrawn
NCT01619670Phase 4

A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa

Terminated
NCT02011724Phase 4

A Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®

Unknown
NCT00587587Phase 1

A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids

Completed
NCT00587223Phase 3

Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
6